Skip to main content
Top
Gepubliceerd in:

01-11-2007 | Original Paper

Relevance of Donepezil in Enhancing Learning and Memory in Special Populations: A Review of the Literature

Auteurs: J. Helen Yoo, Maria G. Valdovinos, Dean C. Williams

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 10/2007

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

This review discusses the laboratory and clinical research supporting the rationale for the efficacy of donepezil (Aricept® USA) in enhancing cognition in autism, Alzheimer disease, Down syndrome, traumatic brain injury, Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia. While preliminary animal models have shown effective, human studies exclusive of Alzheimer disease are sparse. Although attention and memory are unlikely a sole operation of the cholinergic system, evidence indicates a promising direction for further examination of this hypothesis in autism. Studies that examine changes in operationally defined behaviors and reliable and valid measure of changes in attention and memory are needed.
Literatuur
go back to reference American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders text revision. Washington, DC: Author. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders text revision. Washington, DC: Author.
go back to reference Anderson R., & Higgins, G. A. (1997). Absence of central cholinergic deficits in ApoE knockout mice. Psychopharmacology, 132, 135–144.PubMed Anderson R., & Higgins, G. A. (1997). Absence of central cholinergic deficits in ApoE knockout mice. Psychopharmacology, 132, 135–144.PubMed
go back to reference Barnes, C. A., Meltzer, J., Houston, F., Orr, G., McGann, K., & Wenk, G. L. (2000). Chronic treatment of old rats with donepezil or galantamine, effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99, 17–23.PubMed Barnes, C. A., Meltzer, J., Houston, F., Orr, G., McGann, K., & Wenk, G. L. (2000). Chronic treatment of old rats with donepezil or galantamine, effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99, 17–23.PubMed
go back to reference Bauman, M. L., & Kemper, T. L. (1994). Neuroanatomic observations of the brain in autism. In M. L. Bauman, & T. L. Kemper. (Eds.), The neurobiology of autism (pp. 119–145). Baltimore, MD: Johns Hopkins University Press. Bauman, M. L., & Kemper, T. L. (1994). Neuroanatomic observations of the brain in autism. In M. L. Bauman, & T. L. Kemper. (Eds.), The neurobiology of autism (pp. 119–145). Baltimore, MD: Johns Hopkins University Press.
go back to reference Berger-Sweeney, J., & Hohmann, C. F. (1997). Behavioral consequences of abnormal cortical development, insights into developmental disabilities. Behavior and Brain Research, 86, 121–142. Berger-Sweeney, J., & Hohmann, C. F. (1997). Behavioral consequences of abnormal cortical development, insights into developmental disabilities. Behavior and Brain Research, 86, 121–142.
go back to reference Bourgeois, J. A., Bahadur, N., & Minjares, S. (2002). Donepezil for cognitive deficits following traumatic brain injury: A case report. Journal of Neuropsychiatry Clinical Neuroscience, 14, 463–464. Bourgeois, J. A., Bahadur, N., & Minjares, S. (2002). Donepezil for cognitive deficits following traumatic brain injury: A case report. Journal of Neuropsychiatry Clinical Neuroscience, 14, 463–464.
go back to reference Braida, D., Paladini, E., Griffini, P., Lamperti, M., Colibretti, L., & Sala, M. (1998). Long-lasting antiamnesic effect of a novel anticholinesterase inhibitor (MF 268). Pharmacology, Biochemistry, and Behavior, 59, 897–901.PubMed Braida, D., Paladini, E., Griffini, P., Lamperti, M., Colibretti, L., & Sala, M. (1998). Long-lasting antiamnesic effect of a novel anticholinesterase inhibitor (MF 268). Pharmacology, Biochemistry, and Behavior, 59, 897–901.PubMed
go back to reference Buccafusco, J. J., Jackson, W. J., Stone, J. D., & Terry, A. V. (2003). Sex dimorphisms in the cognitive-enhancing action of the Alzheimer’s drug donepezil in aged rhesus monkeys. Neuropharmacology, 44, 381–389.PubMed Buccafusco, J. J., Jackson, W. J., Stone, J. D., & Terry, A. V. (2003). Sex dimorphisms in the cognitive-enhancing action of the Alzheimer’s drug donepezil in aged rhesus monkeys. Neuropharmacology, 44, 381–389.PubMed
go back to reference Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (2002). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Research, 59, 29–33. Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (2002). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Research, 59, 29–33.
go back to reference Bullock, R., & Dengiz, A. (2005). Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. International Journal of Clinical Practice, 59, 817–822.PubMed Bullock, R., & Dengiz, A. (2005). Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. International Journal of Clinical Practice, 59, 817–822.PubMed
go back to reference Carr, E. G., & Durand, V. M. (1985). Reducing behavior problems through functional communication training. Journal of Applied Behavior Analysis, 18, 111–126.PubMed Carr, E. G., & Durand, V. M. (1985). Reducing behavior problems through functional communication training. Journal of Applied Behavior Analysis, 18, 111–126.PubMed
go back to reference Chez, M. G., Aimonovitch, M. C., Buchanan, M. S., Mrazek, S. R., & Tremb, R. J. (2004). Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology, 19, 165–169. Chez, M. G., Aimonovitch, M. C., Buchanan, M. S., Mrazek, S. R., & Tremb, R. J. (2004). Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology, 19, 165–169.
go back to reference Chez, M. G., Buchanan, T. M., Becker, M., Kessler, J., Aimonovitch, M. C., & Mrazek, S. R. (2003). Donepezil hydrochloride: A double-blind study in autistic children. Journal of Pediatric Neurology, 1, 83–88. Chez, M. G., Buchanan, T. M., Becker, M., Kessler, J., Aimonovitch, M. C., & Mrazek, S. R. (2003). Donepezil hydrochloride: A double-blind study in autistic children. Journal of Pediatric Neurology, 1, 83–88.
go back to reference Conners, C. K., Levin, E. D., Sparrow, E., Hinton, S. C., Erhardt, D., Meck, W. H., et al. (1996). Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacology Bulletin, 32, 67–73.PubMed Conners, C. K., Levin, E. D., Sparrow, E., Hinton, S. C., Erhardt, D., Meck, W. H., et al. (1996). Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacology Bulletin, 32, 67–73.PubMed
go back to reference Cooper J. R., Bloom F. E., & Roth R. H. (1996). The biochemical basis of neuropharmacology (pp. 190–219). New York: Oxford University Press. Cooper J. R., Bloom F. E., & Roth R. H. (1996). The biochemical basis of neuropharmacology (pp. 190–219). New York: Oxford University Press.
go back to reference Court, J. A., Martin-Ruiz, C., Graham, A., & Perry, E. (2000). Nicotinic receptor in human brain: Topography and pathology. Journal of Chemical Neuroanatomy, 20, 281–298.PubMed Court, J. A., Martin-Ruiz, C., Graham, A., & Perry, E. (2000). Nicotinic receptor in human brain: Topography and pathology. Journal of Chemical Neuroanatomy, 20, 281–298.PubMed
go back to reference Coyle, J. T., Price, D. L., & de Long, M. R. (1983). Alzheimer’s disease: A disorder of cortical cholinergic innervation. Science, 219, 1184–1190.PubMed Coyle, J. T., Price, D. L., & de Long, M. R. (1983). Alzheimer’s disease: A disorder of cortical cholinergic innervation. Science, 219, 1184–1190.PubMed
go back to reference Csernansky, J. G., Martin, M., Shah, R., Bertchume, A., Colvin, J., & Dong, H. (2005). Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmcology, 8, [Epub ahead of print] Csernansky, J. G., Martin, M., Shah, R., Bertchume, A., Colvin, J., & Dong, H. (2005). Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmcology, 8, [Epub ahead of print]
go back to reference Davis, R. E., Doyle, P. D., Carroll, R. T., Emmerling, M. R., & Jaen, J. (1995). Cholinergic therapies for Alzheimer’s disease. Arzneimittelforschung Drug Research 45, 425–431. Davis, R. E., Doyle, P. D., Carroll, R. T., Emmerling, M. R., & Jaen, J. (1995). Cholinergic therapies for Alzheimer’s disease. Arzneimittelforschung Drug Research 45, 425–431.
go back to reference Davis, P., & Maloney, A. J. (1976). Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet, 2, 1403. Davis, P., & Maloney, A. J. (1976). Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet, 2, 1403.
go back to reference Dong, H., Csernansky, C. A., Martin, M. V., Bertchume, A., Vallera, D., & Csernansky, J. G. (2005). Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer’s disease. Psychopharmacology, 19, [E-pub ahead of print] Dong, H., Csernansky, C. A., Martin, M. V., Bertchume, A., Vallera, D., & Csernansky, J. G. (2005). Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer’s disease. Psychopharmacology, 19, [E-pub ahead of print]
go back to reference Ellis, C. R., Singh, N. N., & Ruane, A. L. (1999). Nutritional, dietary, and hormonal treatments for individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 335–341. Ellis, C. R., Singh, N. N., & Ruane, A. L. (1999). Nutritional, dietary, and hormonal treatments for individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 335–341.
go back to reference Erickson, S. K., Schwarzkopf, S. B., Palumbo, D., Badgley-Fleeman, J., Smirnow, A. M., & Light G. A. (2005). Efficacy and tolerability of low-dose donepezil in schizophrenia. Clinical Neuropharmacology, 28, 179–184.PubMed Erickson, S. K., Schwarzkopf, S. B., Palumbo, D., Badgley-Fleeman, J., Smirnow, A. M., & Light G. A. (2005). Efficacy and tolerability of low-dose donepezil in schizophrenia. Clinical Neuropharmacology, 28, 179–184.PubMed
go back to reference Foldi, N. S., White, R. E. C., & Schaefer, L. A. (2005). Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer’s disease. International Journal of Geriatric Psychiatry, 20, 485–488.PubMed Foldi, N. S., White, R. E. C., & Schaefer, L. A. (2005). Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer’s disease. International Journal of Geriatric Psychiatry, 20, 485–488.PubMed
go back to reference Food and Drug Administration, Aricept (donepezil hydrochloride tablets). Retrieved August 2003, from http,//www.fda.gov/cder/foi/label/2001/20690s16lbl.pdf, 2000, December. Food and Drug Administration, Aricept (donepezil hydrochloride tablets). Retrieved August 2003, from http,//www.fda.gov/cder/foi/label/2001/20690s16lbl.pdf, 2000, December.
go back to reference Freudenreich, O., Herz, L., Deckersbach, T., Evins, A. E., Henderson, D. C., Cather. C., et al. (2005). Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology, 19, [E-pub ahead of print] Freudenreich, O., Herz, L., Deckersbach, T., Evins, A. E., Henderson, D. C., Cather. C., et al. (2005). Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology, 19, [E-pub ahead of print]
go back to reference Frick, K. M., Stearns, N. A., Pan, J. Y., & Berger-Sweeney, J. (2003). Effects of environmental enrichment on spatial memory and neurochemistry in middle-aged mice. Learning and Memory, 10, 187–198.PubMed Frick, K. M., Stearns, N. A., Pan, J. Y., & Berger-Sweeney, J. (2003). Effects of environmental enrichment on spatial memory and neurochemistry in middle-aged mice. Learning and Memory, 10, 187–198.PubMed
go back to reference Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry 51, 349–357.PubMed Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry 51, 349–357.PubMed
go back to reference Giacobini, E. (1993). Pharmacotherapy of Alzheimer’s disease: New drugs and novel strategies. Progress in Brain Research, 98, 447–454.PubMedCrossRef Giacobini, E. (1993). Pharmacotherapy of Alzheimer’s disease: New drugs and novel strategies. Progress in Brain Research, 98, 447–454.PubMedCrossRef
go back to reference Graham, A. J, Martin-Ruiz, C. M., Teaktong, T., Ray, M. A., & Court, J. A. (2002). Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders. Current Drug Targets. CNS and Neurological Disorders, 1, 387–397.PubMed Graham, A. J, Martin-Ruiz, C. M., Teaktong, T., Ray, M. A., & Court, J. A. (2002). Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders. Current Drug Targets. CNS and Neurological Disorders, 1, 387–397.PubMed
go back to reference Hardan, A. Y., & Handen, B. L. (2002). A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 12, 237–241.PubMed Hardan, A. Y., & Handen, B. L. (2002). A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 12, 237–241.PubMed
go back to reference Harris, N. S., Courchesne, E., Townsend, J., Carper, R. A., & Lord, C. (1999). Neuroanatomic contributions to slowed orienting of attention in children with autism. Cognitive Brain Research, 8, 61–71.PubMed Harris, N. S., Courchesne, E., Townsend, J., Carper, R. A., & Lord, C. (1999). Neuroanatomic contributions to slowed orienting of attention in children with autism. Cognitive Brain Research, 8, 61–71.PubMed
go back to reference Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005). Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? American Journal of Psychiatry, 162, 676–682.PubMed Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005). Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? American Journal of Psychiatry, 162, 676–682.PubMed
go back to reference Hayes, R. L, Lyeth, B. G., & Jenkins, L. W. (1989). Neurochemical mechanisms of mild and moderate head injury: Implications for treatment. In H. A. Levin, H. M. Eisenberg, & A. L. Benton (Eds.), Mild head injury (pp. 54–59). New York: Oxford University Press. Hayes, R. L, Lyeth, B. G., & Jenkins, L. W. (1989). Neurochemical mechanisms of mild and moderate head injury: Implications for treatment. In H. A. Levin, H. M. Eisenberg, & A. L. Benton (Eds.), Mild head injury (pp. 54–59). New York: Oxford University Press.
go back to reference Heller, J. H., Spiridigliozzi, G. A., Doraiswamy, P. M., Sullivan, J. A., Crissman, B. G., & Kishnani, P. S. (2004). Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial. American Journal of Medical Genetics, 130A, 325–326.PubMed Heller, J. H., Spiridigliozzi, G. A., Doraiswamy, P. M., Sullivan, J. A., Crissman, B. G., & Kishnani, P. S. (2004). Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial. American Journal of Medical Genetics, 130A, 325–326.PubMed
go back to reference Heller, J. H., Spiridigliozzi, G. A, Sullivan, J. A., Doraiswamy, P. M., Krishnan, R. R., & Kishnani, P. S. (2003). Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24-week open trial. American Journal of Medical Genetics, 116A, 111–116.PubMed Heller, J. H., Spiridigliozzi, G. A, Sullivan, J. A., Doraiswamy, P. M., Krishnan, R. R., & Kishnani, P. S. (2003). Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24-week open trial. American Journal of Medical Genetics, 116A, 111–116.PubMed
go back to reference Hertzman, M. (2003). Galantamine in the treatment of adult autism: A report of three clinical cases. International Journal of Psychiatry in Medicine 33, 395–398.PubMed Hertzman, M. (2003). Galantamine in the treatment of adult autism: A report of three clinical cases. International Journal of Psychiatry in Medicine 33, 395–398.PubMed
go back to reference Hohmann, C. F., & Berger-Sweeney, J. (1998). Cholinergic regulation of cortical development and plasticity: New twists to an old story. Perspectives on Developmental Neurobiology, 5, 401–425.PubMed Hohmann, C. F., & Berger-Sweeney, J. (1998). Cholinergic regulation of cortical development and plasticity: New twists to an old story. Perspectives on Developmental Neurobiology, 5, 401–425.PubMed
go back to reference Hoopes, S. P. (1999). Donepezil for Tourette’s disorder and ADHD. Journal of Clinical Psychopharmacology, 19, 381–382.PubMed Hoopes, S. P. (1999). Donepezil for Tourette’s disorder and ADHD. Journal of Clinical Psychopharmacology, 19, 381–382.PubMed
go back to reference Howard, A. K., Thornton, A. E., Altman, S., & Honer, W. G. (2002). Donepezil for memory dysfunction in schizophrenia. Journal of Psychopharmacology, 16, 267–270.PubMed Howard, A. K., Thornton, A. E., Altman, S., & Honer, W. G. (2002). Donepezil for memory dysfunction in schizophrenia. Journal of Psychopharmacology, 16, 267–270.PubMed
go back to reference Kahng, S., Iwata, B. A., & Lewin, A. B. (2002). The impact of functional assessment on the treatment of self-injurious behavior. In S. R. Schroeder, M. L. Oster-Granite, & T. L. Thompson (Eds.), Self-injurious behavior: Gene–brain-behavior relationships (pp. 119–131). Washington, DC: American Psychological Association Kahng, S., Iwata, B. A., & Lewin, A. B. (2002). The impact of functional assessment on the treatment of self-injurious behavior. In S. R. Schroeder, M. L. Oster-Granite, & T. L. Thompson (Eds.), Self-injurious behavior: Gene–brain-behavior relationships (pp. 119–131). Washington, DC: American Psychological Association
go back to reference Kandel, E. R. (2001). The molecular biology of memory storage: A dialogue between genes and synapses. Science, 294, 1030–1038.PubMed Kandel, E. R. (2001). The molecular biology of memory storage: A dialogue between genes and synapses. Science, 294, 1030–1038.PubMed
go back to reference Kaye, N. S., Townsend, J. B., & Ivins, R. (2003). An open-label trial of donepezil (Aricept) in the treatment of persons with mild traumatic brain injury. Journal of Neuropsychiatry and Clinical Neuroscience, 15, 383–384. Kaye, N. S., Townsend, J. B., & Ivins, R. (2003). An open-label trial of donepezil (Aricept) in the treatment of persons with mild traumatic brain injury. Journal of Neuropsychiatry and Clinical Neuroscience, 15, 383–384.
go back to reference Khateb, A., Ammann, J., Annoni, J. M., & Diserens, K. (2005). Cognition-enhancing effects of donepezil in traumatic brain injury. European Neurology, 54, 39–45.PubMed Khateb, A., Ammann, J., Annoni, J. M., & Diserens, K. (2005). Cognition-enhancing effects of donepezil in traumatic brain injury. European Neurology, 54, 39–45.PubMed
go back to reference Kishnani, P. S., Sullivan, J. A., Walter, B. K., Spiridigliozzi, G., Doraiswamy, P. M., & Krishnan, K. R. R. (1999). Cholinergic therapy for Down’s syndrome. Lancet, 353, 1064–1065.PubMed Kishnani, P. S., Sullivan, J. A., Walter, B. K., Spiridigliozzi, G., Doraiswamy, P. M., & Krishnan, K. R. R. (1999). Cholinergic therapy for Down’s syndrome. Lancet, 353, 1064–1065.PubMed
go back to reference Kondoh, T., Amamoto, N., Doi, T., Hamada, H., Ogawa, Y., Nakashima, M., et al. (2005). Dramatic improvement in Down syndrome–associated cognitive impairment with donepezil. Annals of Pharmacotherapy, 39, 563–566.PubMed Kondoh, T., Amamoto, N., Doi, T., Hamada, H., Ogawa, Y., Nakashima, M., et al. (2005). Dramatic improvement in Down syndrome–associated cognitive impairment with donepezil. Annals of Pharmacotherapy, 39, 563–566.PubMed
go back to reference Kosasa, T., Kuriya, Y., Matsui, K., & Yamanishi, Y. (1999). Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. European Journal of Pharmacology, 10, 7–13. Kosasa, T., Kuriya, Y., Matsui, K., & Yamanishi, Y. (1999). Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. European Journal of Pharmacology, 10, 7–13.
go back to reference Krnjevic, K., & Reinhardt, W. (1979). Choline excites cortical neurons. Science, 206, 1321–1323.PubMed Krnjevic, K., & Reinhardt, W. (1979). Choline excites cortical neurons. Science, 206, 1321–1323.PubMed
go back to reference Lee, M., Martin-Ruiz, C., Graham, A., Court, J., Jaros, E., Perry, R., et al. (2002). Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain, 125, 1483–1495.PubMed Lee, M., Martin-Ruiz, C., Graham, A., Court, J., Jaros, E., Perry, R., et al. (2002). Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain, 125, 1483–1495.PubMed
go back to reference Levin, E. D. (1992). Nicotinic systems and cognitive function. Psychopharmacology, 108, 417–431.PubMed Levin, E. D. (1992). Nicotinic systems and cognitive function. Psychopharmacology, 108, 417–431.PubMed
go back to reference Levin, E. D. (2000). The role of nicotinic acetylcholine receptors in cognitive function. In F. Clementi, D. Fornasari, & C. Gotti (Eds.), Neuronal nicotinic receptors: Experimental pharmacology (pp. 587–602). Berlin: Springer. Levin, E. D. (2000). The role of nicotinic acetylcholine receptors in cognitive function. In F. Clementi, D. Fornasari, & C. Gotti (Eds.), Neuronal nicotinic receptors: Experimental pharmacology (pp. 587–602). Berlin: Springer.
go back to reference Levin, E. D., Conners, C., Sparrow, E., Hinton, S., Erhardt, D., & Meck, W., et al. (1996). Nicotine effects on adults with attention deficit hyperactivity disorder. Psychopharmacology, 123, 55–63.PubMed Levin, E. D., Conners, C., Sparrow, E., Hinton, S., Erhardt, D., & Meck, W., et al. (1996). Nicotine effects on adults with attention deficit hyperactivity disorder. Psychopharmacology, 123, 55–63.PubMed
go back to reference Levin, E. D., Lee, C., Rose, J. E., Reyes, A., Ellison, G., Jarvik, M., & Gritz, E. (1990). Chronic nicotine and withdrawal effects on radial arm maze performance in rats. Behavioral and Neural Biology, 53, 269–276.PubMed Levin, E. D., Lee, C., Rose, J. E., Reyes, A., Ellison, G., Jarvik, M., & Gritz, E. (1990). Chronic nicotine and withdrawal effects on radial arm maze performance in rats. Behavioral and Neural Biology, 53, 269–276.PubMed
go back to reference Levin, E. D., & Torry, D. (1996). Acute and chronic nicotine effects of working memory in aged rats. Psychopharmacology, 123, 217–230. Levin, E. D., & Torry, D. (1996). Acute and chronic nicotine effects of working memory in aged rats. Psychopharmacology, 123, 217–230.
go back to reference Lindsay, R. L., & Aman, M. M. (2003). Pharmacologic therapies aid treatment for autism. Pediatric Annals, 32, 671–676.PubMed Lindsay, R. L., & Aman, M. M. (2003). Pharmacologic therapies aid treatment for autism. Pediatric Annals, 32, 671–676.PubMed
go back to reference Lott, I. T., Osann, K., Doran, E., & Nelson, L. (2002). Down syndrome and Alzheimer disease, response to donepezil. Archives of Neurology, 59, 1133–1136.PubMed Lott, I. T., Osann, K., Doran, E., & Nelson, L. (2002). Down syndrome and Alzheimer disease, response to donepezil. Archives of Neurology, 59, 1133–1136.PubMed
go back to reference Luine, V. N., Mohan, G., Tu, Z., & Efange, S. M. N. (2002). Chromaproline and chromaperidine, nicotine agonists, and donepezil cholinesterase inhibitor, enhance performance of memory tasks in ovariectomized rats. Pharmacology, Biochemistry, and Behavior, 74, 213–220.PubMed Luine, V. N., Mohan, G., Tu, Z., & Efange, S. M. N. (2002). Chromaproline and chromaperidine, nicotine agonists, and donepezil cholinesterase inhibitor, enhance performance of memory tasks in ovariectomized rats. Pharmacology, Biochemistry, and Behavior, 74, 213–220.PubMed
go back to reference MacEwan, G. W., Ehmann, T. S., Khanbhai, I., & Wrixon, C. (2001). Donepezil in schizophrenia – is it helpful? An experimental design case study. Acta Psychiatrica Scandinavica, 104, 469–471.PubMed MacEwan, G. W., Ehmann, T. S., Khanbhai, I., & Wrixon, C. (2001). Donepezil in schizophrenia – is it helpful? An experimental design case study. Acta Psychiatrica Scandinavica, 104, 469–471.PubMed
go back to reference Mann, E. M. A. (1988). Alzheimer’s disease and Down’s syndrome. Histopathology, 13, 125–137.PubMed Mann, E. M. A. (1988). Alzheimer’s disease and Down’s syndrome. Histopathology, 13, 125–137.PubMed
go back to reference Mann, E. M. A., & Esiri, M. M. (1989). The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down’s syndrome. Journal of the Neurological Sciences, 89, 169–179.PubMed Mann, E. M. A., & Esiri, M. M. (1989). The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down’s syndrome. Journal of the Neurological Sciences, 89, 169–179.PubMed
go back to reference Masanic, C. A., Bayley, M. T., van Reekum, R., & Simard, M. (2001). Open-label study of donepezil in traumatic brain injury. Archives of Physical Medicine and Rehabilitation, 82, 896–901.PubMed Masanic, C. A., Bayley, M. T., van Reekum, R., & Simard, M. (2001). Open-label study of donepezil in traumatic brain injury. Archives of Physical Medicine and Rehabilitation, 82, 896–901.PubMed
go back to reference McCracken, J. T., McGough, J., Shah, B, Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D. (Research Units on Pediatric Psychopharmacology Autism Network). (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314–321.PubMed McCracken, J. T., McGough, J., Shah, B, Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D. (Research Units on Pediatric Psychopharmacology Autism Network). (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314–321.PubMed
go back to reference McDonald, M. P., & Overmeier, J. B. (1998). Present imperfect: A critical review of animal models of the mnemonic impairments in Alzheimer’s disease. Neuroscience & Biobehavioral Reviews, 22, 99–120. McDonald, M. P., & Overmeier, J. B. (1998). Present imperfect: A critical review of animal models of the mnemonic impairments in Alzheimer’s disease. Neuroscience & Biobehavioral Reviews, 22, 99–120.
go back to reference McEachin, J. J., Smith, T., & Lovaas, O. I. (1993). Long-term outcome for children with autism who received early intensive behavioral treatment. American Journal on Mental Retardation, 97, 359–72.PubMed McEachin, J. J., Smith, T., & Lovaas, O. I. (1993). Long-term outcome for children with autism who received early intensive behavioral treatment. American Journal on Mental Retardation, 97, 359–72.PubMed
go back to reference Meyer, J. S., Chowdhury, M. H., Xu, G., Li, Y., & Wuach, M. (2002). Donepezil treatment of vascular dementia. Annals of the New York Academy of Sciences, 977, 482–486.PubMed Meyer, J. S., Chowdhury, M. H., Xu, G., Li, Y., & Wuach, M. (2002). Donepezil treatment of vascular dementia. Annals of the New York Academy of Sciences, 977, 482–486.PubMed
go back to reference Mirza, N. R., & Stolerman, I. P. (2000). The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacologia, 148, 243–250. Mirza, N. R., & Stolerman, I. P. (2000). The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacologia, 148, 243–250.
go back to reference Morey, C. E., Cilo, M., Berry, J., & Cusik, C. (2003). The effect of Aricept® in persons with persistent memory disorder following traumatic brain injury: A pilot study. Brain Injury, 17, 809–815.PubMed Morey, C. E., Cilo, M., Berry, J., & Cusik, C. (2003). The effect of Aricept® in persons with persistent memory disorder following traumatic brain injury: A pilot study. Brain Injury, 17, 809–815.PubMed
go back to reference Mori, S. (2002). Response to donepezil in Alzheimer’s disease and Parkinson’s disease. Annals of the New York Academy of Sciences, 977, 493–500.PubMedCrossRef Mori, S. (2002). Response to donepezil in Alzheimer’s disease and Parkinson’s disease. Annals of the New York Academy of Sciences, 977, 493–500.PubMedCrossRef
go back to reference Myhrer, T. (2003). Neurotransmitter systems involved in learning and memory in the rat: A meta-analysis based on studies of four behavioral tasks. Brain research. Brain research reviews, 41, 268–287.PubMed Myhrer, T. (2003). Neurotransmitter systems involved in learning and memory in the rat: A meta-analysis based on studies of four behavioral tasks. Brain research. Brain research reviews, 41, 268–287.PubMed
go back to reference Nahas, Z., George, M. S., Horner, M. D., Markowitz, J. S., Li, X., & Lorberbaum, J. P., et al. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study. Neurocase, 9, 274–282.PubMed Nahas, Z., George, M. S., Horner, M. D., Markowitz, J. S., Li, X., & Lorberbaum, J. P., et al. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study. Neurocase, 9, 274–282.PubMed
go back to reference Narahashi, T., Moriguchi, S., Zhao, X., Marszalec, W., & Yeh, J. Z. (2004). Mechanisms of action of cognitive enhancers on neuroreceptors. Biological & Pharmaceutical Bulletin, 27, 1701–1706.PubMed Narahashi, T., Moriguchi, S., Zhao, X., Marszalec, W., & Yeh, J. Z. (2004). Mechanisms of action of cognitive enhancers on neuroreceptors. Biological & Pharmaceutical Bulletin, 27, 1701–1706.PubMed
go back to reference National Institute of Mental Health, CGI (Clinical Global Impression) scale. (1985). Psychopharmacology Bulletin, 21, 839–843. National Institute of Mental Health, CGI (Clinical Global Impression) scale. (1985). Psychopharmacology Bulletin, 21, 839–843.
go back to reference Niederhofer, H., Staffen, W., & Mair, A. (2002). Galantamine may be effective in treating autistic disorder. British Journal of Medicine, 325, 1422. Niederhofer, H., Staffen, W., & Mair, A. (2002). Galantamine may be effective in treating autistic disorder. British Journal of Medicine, 325, 1422.
go back to reference Newhouse, P. A., Potter, A., Corwin, J., & Lenox, R. (1992). Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology, 108, 480–484.PubMed Newhouse, P. A., Potter, A., Corwin, J., & Lenox, R. (1992). Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology, 108, 480–484.PubMed
go back to reference Nicolodi, M., Galeotti, N., Ghelardini, C., Cartolini, A., & Sicuteri, F. (2002). Central cholinergic challenging of migraine by testing second-generation anticholinesterase drugs. Headache, 42, 596–602.PubMed Nicolodi, M., Galeotti, N., Ghelardini, C., Cartolini, A., & Sicuteri, F. (2002). Central cholinergic challenging of migraine by testing second-generation anticholinesterase drugs. Headache, 42, 596–602.PubMed
go back to reference Nordberg, A. (2001). Nicotinic receptor abnormalities of Alzheimer’s disease: Therapeutic implications. Biological Psychiatry, 49, 200–210.PubMed Nordberg, A. (2001). Nicotinic receptor abnormalities of Alzheimer’s disease: Therapeutic implications. Biological Psychiatry, 49, 200–210.PubMed
go back to reference Owley, T., McMahon, W., Cook, E. H., Laulhere, T., South, M., & Mays, L. Z., et al. (2001). Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1293–1299.PubMed Owley, T., McMahon, W., Cook, E. H., Laulhere, T., South, M., & Mays, L. Z., et al. (2001). Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1293–1299.PubMed
go back to reference Owley, T., Steele, E., Corsello, C., Risi, S., McKaig, K., & Lord, C., et al. (1999). A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape General Medicine, October, E2. Owley, T., Steele, E., Corsello, C., Risi, S., McKaig, K., & Lord, C., et al. (1999). A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape General Medicine, October, E2.
go back to reference Paterson, D., & Nordberg, A. (2000). Neuronal nicotinic receptors in the human brain. Progress in Neurobiology, 61, 71–111. Paterson, D., & Nordberg, A. (2000). Neuronal nicotinic receptors in the human brain. Progress in Neurobiology, 61, 71–111.
go back to reference Perry, E. K., Lee, M. L. W., Martin-Ruiz, C. M., Court, J. A., Volsen, S. G., & Merrit, J., et al. (2001). Cholinergic activities in autism, Abnormalities in the cerebral cortex and basal forebrain. American Journal of Psychiatry, 158, 1058–1066.PubMed Perry, E. K., Lee, M. L. W., Martin-Ruiz, C. M., Court, J. A., Volsen, S. G., & Merrit, J., et al. (2001). Cholinergic activities in autism, Abnormalities in the cerebral cortex and basal forebrain. American Journal of Psychiatry, 158, 1058–1066.PubMed
go back to reference Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., Perry, R. H. (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal, 2, 1457–1459.PubMedCrossRef Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., Perry, R. H. (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal, 2, 1457–1459.PubMedCrossRef
go back to reference Prasher, V. P., Adams, C., Holder, R., & Down Syndrome Research Group. (2003). Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome, Open label study. International Journal of Geriatric Psychiatry, 18, 549–551.PubMed Prasher, V. P., Adams, C., Holder, R., & Down Syndrome Research Group. (2003). Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome, Open label study. International Journal of Geriatric Psychiatry, 18, 549–551.PubMed
go back to reference Prasher, V. P., Huxley, A., & Haque, M. S. (2002). The Down syndrome ageing study group, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer’s disease – pilot study. International Journal of Geriatric Psychiatry, 17, 270–278.PubMed Prasher, V. P., Huxley, A., & Haque, M. S. (2002). The Down syndrome ageing study group, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer’s disease – pilot study. International Journal of Geriatric Psychiatry, 17, 270–278.PubMed
go back to reference Pratt, R. D., Perdomo, C. A., Surick, I. W., & Ieni, J. R. (2002). Donepezil, tolerability and safety in Alzheimer’s disease. International Journal Clinical Practice, 56, 710–717. Pratt, R. D., Perdomo, C. A., Surick, I. W., & Ieni, J. R. (2002). Donepezil, tolerability and safety in Alzheimer’s disease. International Journal Clinical Practice, 56, 710–717.
go back to reference Pratt, R. D., & Perdomo, C. A., & The donepezil VaD 307 and 308 study groups. (2002). Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Annals of the New York Academy of Sciences, 977, 513–522. Pratt, R. D., & Perdomo, C. A., & The donepezil VaD 307 and 308 study groups. (2002). Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Annals of the New York Academy of Sciences, 977, 513–522.
go back to reference Prickaerts, J., Şık, A., van der Staay, F. J., de Vente, J., & Blokland, A. (2005). Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: Acquisition versus consolidation. Psychopharmacology, 177, 381–390.PubMed Prickaerts, J., Şık, A., van der Staay, F. J., de Vente, J., & Blokland, A. (2005). Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: Acquisition versus consolidation. Psychopharmacology, 177, 381–390.PubMed
go back to reference Reed, P., & Gibson, E. (2005). The effect of concurrent task load on stimulus over-selectivity. Journal of Autism Developmental Disorders, 35, 601–614. Reed, P., & Gibson, E. (2005). The effect of concurrent task load on stimulus over-selectivity. Journal of Autism Developmental Disorders, 35, 601–614.
go back to reference Risch, S. C., McGurk, S., Horner, M. D., Nahas, Z., Owens, S. D., & Molloy, M., et al. (2001). A double-blind pacebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient, Functional MRI correlates. Neurocase, 7, 105–110.PubMed Risch, S. C., McGurk, S., Horner, M. D., Nahas, Z., Owens, S. D., & Molloy, M., et al. (2001). A double-blind pacebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient, Functional MRI correlates. Neurocase, 7, 105–110.PubMed
go back to reference Rogers, S. L., Doody, R. S., Mohs, R. C., Friedhoff, L. T., & The donepezil study group. (1998a). Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine, 158, 1021–1031. Rogers, S. L., Doody, R. S., Mohs, R. C., Friedhoff, L. T., & The donepezil study group. (1998a). Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine, 158, 1021–1031.
go back to reference Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R. C., Friedhoff, L. T., & The donepezil study group. (1998b). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology, 50, 136–145. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R. C., Friedhoff, L. T., & The donepezil study group. (1998b). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology, 50, 136–145.
go back to reference Rogers, S. L., & Friedhoff, L. T. (1998). Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: An interim analysis of the results of a US multicenter open label extension study. European Neuropsychopharmacology, 8, 67–75.PubMed Rogers, S. L., & Friedhoff, L. T. (1998). Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: An interim analysis of the results of a US multicenter open label extension study. European Neuropsychopharmacology, 8, 67–75.PubMed
go back to reference Rogers, S. L., Friedhoff, L. T., & The donepezil study group. (1996). The efficacy and safety of donepezil in patients with Alzheimer’s disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia, 7, 293–303.PubMed Rogers, S. L., Friedhoff, L. T., & The donepezil study group. (1996). The efficacy and safety of donepezil in patients with Alzheimer’s disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia, 7, 293–303.PubMed
go back to reference Rogers, S. L., Yamanishi, Y., & Yamatsu, K. (1991). E2020-The pharmacology of a piperidine cholinesterase inhibitor. In R. Becker & E. Giacobini (Eds.), Cholinergic basis for Alzheimer therapy (pp. 314–320). Boston: Birkhauser. Rogers, S. L., Yamanishi, Y., & Yamatsu, K. (1991). E2020-The pharmacology of a piperidine cholinesterase inhibitor. In R. Becker & E. Giacobini (Eds.), Cholinergic basis for Alzheimer therapy (pp. 314–320). Boston: Birkhauser.
go back to reference Rosenthal, R. (1991). Meta-analysis: A review. Psychosomatic Medicine, 53, 247–271.PubMed Rosenthal, R. (1991). Meta-analysis: A review. Psychosomatic Medicine, 53, 247–271.PubMed
go back to reference Rosenzweig, M. R., & Bennett, E. L. (1996). Psychobiology of plasticity. Effects of training and experience on brain and behavior. Behavioural Brain Research, 78, 57–65.PubMed Rosenzweig, M. R., & Bennett, E. L. (1996). Psychobiology of plasticity. Effects of training and experience on brain and behavior. Behavioural Brain Research, 78, 57–65.PubMed
go back to reference Rupniak, N. M. J., Tye, S. J., & Field, M. J. (1997). Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology, 131, 406–410.PubMed Rupniak, N. M. J., Tye, S. J., & Field, M. J. (1997). Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology, 131, 406–410.PubMed
go back to reference Rusted, J., Graupner, L., O’Connell, N., & Nicholls, C. (1994). Does nicotine improve cognitive function? Psychopharmacology, 115, 547–549.PubMed Rusted, J., Graupner, L., O’Connell, N., & Nicholls, C. (1994). Does nicotine improve cognitive function? Psychopharmacology, 115, 547–549.PubMed
go back to reference Sarter, M., & Bruno, J. P. (1999). Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends in Neuroscience, 22, 67–74. Sarter, M., & Bruno, J. P. (1999). Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends in Neuroscience, 22, 67–74.
go back to reference Schupf, N., Kapell, D., Nightingale, B., Rodriguez, A., Tycko, B., & Mayeux, R. (1998). Earlier onset of Alzheimer’s disease in men with Down syndrome. Neurology, 40, 991–995. Schupf, N., Kapell, D., Nightingale, B., Rodriguez, A., Tycko, B., & Mayeux, R. (1998). Earlier onset of Alzheimer’s disease in men with Down syndrome. Neurology, 40, 991–995.
go back to reference Seltzer, B., Zolnouni, P., Nunez, M., Goldman R, Kumar, D., & Ieni, J., et al. (2004). Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Archives of Neurology, 61, 1852–1856.PubMed Seltzer, B., Zolnouni, P., Nunez, M., Goldman R, Kumar, D., & Ieni, J., et al. (2004). Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Archives of Neurology, 61, 1852–1856.PubMed
go back to reference Smith, T., Eikeseth, S., Klevstrand, M., & Lovaas, O. I. (1997). Intensive behavioral treatment for preschoolers with severe mental retardation and pervasive developmental disorder. American Journal on Mental Retardation, 102, 238–249.PubMed Smith, T., Eikeseth, S., Klevstrand, M., & Lovaas, O. I. (1997). Intensive behavioral treatment for preschoolers with severe mental retardation and pervasive developmental disorder. American Journal on Mental Retardation, 102, 238–249.PubMed
go back to reference Smith, T. (1999). Outcome of early intervention for children with autism. Clinical Psychology: Science and Practice, 6, 33–49. Smith, T. (1999). Outcome of early intervention for children with autism. Clinical Psychology: Science and Practice, 6, 33–49.
go back to reference Sokol, D. K., Dunn, D. W., Edwards-Brown, M., & Feinberg, J. (2002). Hydrogen proton magnetic resonance spectroscopy in autism: Preliminary evidence of elevated choline/creatine ratio. Journal of Child Neurology, 17, 245–249.PubMed Sokol, D. K., Dunn, D. W., Edwards-Brown, M., & Feinberg, J. (2002). Hydrogen proton magnetic resonance spectroscopy in autism: Preliminary evidence of elevated choline/creatine ratio. Journal of Child Neurology, 17, 245–249.PubMed
go back to reference Spowart-Manning, L., & van der Staay, F. J. (2004). The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behavioural Brain Research, 151, 37–46.PubMed Spowart-Manning, L., & van der Staay, F. J. (2004). The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behavioural Brain Research, 151, 37–46.PubMed
go back to reference Spowart-Manning, L., & van der Staay, F. J. (2005). Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task. Behavioural Brain Research, 156, 269–276.PubMed Spowart-Manning, L., & van der Staay, F. J. (2005). Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task. Behavioural Brain Research, 156, 269–276.PubMed
go back to reference Stahl, S. M. (2000). Essential psychopharmacology: Neuroscientific basis and practical applications. New York: Cambridge University Press. Stahl, S. M. (2000). Essential psychopharmacology: Neuroscientific basis and practical applications. New York: Cambridge University Press.
go back to reference Stryjer, R., Strous, R., Bar, F., Werber, E., Shaked, G., & Buhiri, Y., et al. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology, 26, 12–17.PubMed Stryjer, R., Strous, R., Bar, F., Werber, E., Shaked, G., & Buhiri, Y., et al. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology, 26, 12–17.PubMed
go back to reference Sugimoto, H. (2001). Donepezil hydrochloride, a treatment drug for Alzheimer’s disease. Chemical Reactions, 1, 63–73. Sugimoto, H. (2001). Donepezil hydrochloride, a treatment drug for Alzheimer’s disease. Chemical Reactions, 1, 63–73.
go back to reference Takahata, K., Minami, A., Kusumoto, H., Shimazu, S., & Yoneda, F. (2005). Effects of selegiline alone or with donepezil on memory impairment in rats. European Journal of Pharmacology, 518, 140–144.PubMed Takahata, K., Minami, A., Kusumoto, H., Shimazu, S., & Yoneda, F. (2005). Effects of selegiline alone or with donepezil on memory impairment in rats. European Journal of Pharmacology, 518, 140–144.PubMed
go back to reference Taverni, J. P., Seliger, G., & Lichtman, S. W. (1998). Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Injury, 12, 77–80.PubMed Taverni, J. P., Seliger, G., & Lichtman, S. W. (1998). Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Injury, 12, 77–80.PubMed
go back to reference Tenovuo, O. (2005). Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury – clinical experience in 111 patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29, 61–67.PubMed Tenovuo, O. (2005). Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury – clinical experience in 111 patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29, 61–67.PubMed
go back to reference Tokita, K., Yamazaki, S., Yamazaki, M., Matsuoka, N., & Mutoh, S. (2002). Combination of a novel antidementia drug FK 960 with donepezil synergistically improves memory deficits in rats. Pharmacology, Biochemistry, and Behavior, 73, 511–519.PubMed Tokita, K., Yamazaki, S., Yamazaki, M., Matsuoka, N., & Mutoh, S. (2002). Combination of a novel antidementia drug FK 960 with donepezil synergistically improves memory deficits in rats. Pharmacology, Biochemistry, and Behavior, 73, 511–519.PubMed
go back to reference Tsai, L. Y. (1999). Pharmacology in autism. Psychosomatic Medicine, 61, 651–665.PubMed Tsai, L. Y. (1999). Pharmacology in autism. Psychosomatic Medicine, 61, 651–665.PubMed
go back to reference Tsukada, H., Nishiyama, S., Fukumoto, D., Ohba, H., Sata, K., & Kakiuchi, T. (2004). Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse, 52, 1–10.PubMed Tsukada, H., Nishiyama, S., Fukumoto, D., Ohba, H., Sata, K., & Kakiuchi, T. (2004). Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse, 52, 1–10.PubMed
go back to reference Tuğal, Ö., Yazıcı, K. M., Yağcıoğlu, A. E. A., & Göğüş, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology, 7, 117–123.PubMed Tuğal, Ö., Yazıcı, K. M., Yağcıoğlu, A. E. A., & Göğüş, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology, 7, 117–123.PubMed
go back to reference Van Dam, D., Abramowski, D., Staufenbiel, M., & De Deyn, P. P. (2005). Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology, 180, 177–190.PubMed Van Dam, D., Abramowski, D., Staufenbiel, M., & De Deyn, P. P. (2005). Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology, 180, 177–190.PubMed
go back to reference Van Reekum, R., Black, S.E., Conn, D., & Clarke, D. (1997). Cognition-enhancing drugs in dementia: A guide to the near future. Canadian Journal of Psychiatry, 42, 35S–50S. Van Reekum, R., Black, S.E., Conn, D., & Clarke, D. (1997). Cognition-enhancing drugs in dementia: A guide to the near future. Canadian Journal of Psychiatry, 42, 35S–50S.
go back to reference Walker, W., Seel, R., Gibellato, M., Lew, H., Cornis-Pop, M, & Jena, T., et al. (2004). The effects of donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Injury, 18, 739–750.PubMed Walker, W., Seel, R., Gibellato, M., Lew, H., Cornis-Pop, M, & Jena, T., et al. (2004). The effects of donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Injury, 18, 739–750.PubMed
go back to reference Whelan, F. J., Walker, M. S., & Schultz, S. K. (2000). Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Annals of Clinical Psychiatry, 12, 131–135.PubMed Whelan, F. J., Walker, M. S., & Schultz, S. K. (2000). Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Annals of Clinical Psychiatry, 12, 131–135.PubMed
go back to reference White, K. G., & Ruske, A. C. (2002). Memory deficits in Alzheimer’s disease: The encoding hypothesis and cholinergic function. Psychonomic Bulletin & Review, 9, 426–437. White, K. G., & Ruske, A. C. (2002). Memory deficits in Alzheimer’s disease: The encoding hypothesis and cholinergic function. Psychonomic Bulletin & Review, 9, 426–437.
go back to reference Whitehead, A., Perdomo, C., Pratt, R. D., Birks, J., Wilcock, G. K., & Evans, J. G. (2004). Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: A meta-analysis of individual patient data from randomised controlled trials. International Journal of Geriatric Psychiatry, 19, 624–633.PubMed Whitehead, A., Perdomo, C., Pratt, R. D., Birks, J., Wilcock, G. K., & Evans, J. G. (2004). Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: A meta-analysis of individual patient data from randomised controlled trials. International Journal of Geriatric Psychiatry, 19, 624–633.PubMed
go back to reference Whitlock, J. (1999). Brain injury, cognitive impairment, and donepezil. Journal of Head Trauma Rehabilitation, 14, 424–427.PubMed Whitlock, J. (1999). Brain injury, cognitive impairment, and donepezil. Journal of Head Trauma Rehabilitation, 14, 424–427.PubMed
go back to reference Wilens, T. E., Biederman, J., Wong, J., Spencer, T. J., & Prince, J. B. (2000). Adjunctive donepezil in attention deficit hyperactivity disorder youth: Case series. Journal of Child and Adolescent Psychopharmacology, 10, 217–222.PubMed Wilens, T. E., Biederman, J., Wong, J., Spencer, T. J., & Prince, J. B. (2000). Adjunctive donepezil in attention deficit hyperactivity disorder youth: Case series. Journal of Child and Adolescent Psychopharmacology, 10, 217–222.PubMed
go back to reference Williams, D. C., & Saunders, K. J. (1997). Methodological issues in the study of drug effects on cognitive skills in mental retardation. International Review of Research in Mental Retardation, 21, 147–185.CrossRef Williams, D. C., & Saunders, K. J. (1997). Methodological issues in the study of drug effects on cognitive skills in mental retardation. International Review of Research in Mental Retardation, 21, 147–185.CrossRef
go back to reference Zhang, L., Plotkin, R. C., Wang, G., Sandel, E., & Lee, S. (2004). Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Archives of Physical Medicine and Rehabilitation, 85, 1050–1055.PubMed Zhang, L., Plotkin, R. C., Wang, G., Sandel, E., & Lee, S. (2004). Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Archives of Physical Medicine and Rehabilitation, 85, 1050–1055.PubMed
go back to reference Zhang, L., Zhou, F. M., & Dani, J. A. (2004). Cholinergic drugs for Alzheimer’s disease enhance in vitro dopamine release. Molecular Pharmacology, 66, 538–544.PubMed Zhang, L., Zhou, F. M., & Dani, J. A. (2004). Cholinergic drugs for Alzheimer’s disease enhance in vitro dopamine release. Molecular Pharmacology, 66, 538–544.PubMed
go back to reference Zigman, W. B., Schupf, N., Devenny, D. A., Miezejeski, C., Ryan, R., & Urv, T. K., et al. (1995). Incidence and prevalence of dementia in adults with and without Down syndrome. American Journal on Mental Retardation, 100, 403–412. Zigman, W. B., Schupf, N., Devenny, D. A., Miezejeski, C., Ryan, R., & Urv, T. K., et al. (1995). Incidence and prevalence of dementia in adults with and without Down syndrome. American Journal on Mental Retardation, 100, 403–412.
Metagegevens
Titel
Relevance of Donepezil in Enhancing Learning and Memory in Special Populations: A Review of the Literature
Auteurs
J. Helen Yoo
Maria G. Valdovinos
Dean C. Williams
Publicatiedatum
01-11-2007
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 10/2007
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-006-0322-8